Synageva BioPharma Corp. (Synageva) GEVA, a biopharmaceutical company developing therapeutic products for rare diseases, will report 2013 fourth quarter and full year financial results after the NASDAQ Market closes on Monday, March 3, 2014. Synageva management will conduct a conference call and audio webcast to discuss these results as well as provide a general business update at 4:30 p.m. EST on the same day.
Dial-in number for the conference call:
U.S. (877) 445-4603
International
(443) 295-9270
A live webcast of the call will be available from the “Webcasts & Presentations” section of the Investor Relations tab on the home page of Synageva's website at www.synageva.com.
Synageva routinely posts information that may be important to investors in the “Investor Relations” section of the company's website at www.synageva.com. Synageva encourages investors and potential investors to consult this website regularly for important information about the company.
Further information regarding Synageva BioPharma Corp. is available at www.synageva.com.
Forward-Looking Statements
This news release contains
“forward-looking statements”. Such statements generally can be
identified by the use of words such as “anticipate,” “expect,” “plan,”
“could,” “intend,” “believe,” “may,” “will,” “estimate,” “forecast,”
“project,” or words of similar meaning. Many factors may cause actual
results to differ materially from those expressed or implied by
forward-looking statements, including inaccurate assumptions and a broad
variety of risks and uncertainties, including, risk of delays in
completing our clinical trials, risk that the outcomes of our clinical
trials may not support registration or further development of our
product candidates due to safety, efficacy or other reasons, the content
and timing of decisions by the U.S. Food and Drug Administration and
other regulatory authorities, and the risks identified under the heading
“Risk Factors” in Synageva's Quarterly Report on Form 10-Q filed with
the Securities and Exchange Commission (the “SEC”) on November 4, 2013
and other filings Synageva periodically makes with the SEC, and others
of which are not known. No forward-looking statement is a guarantee of
future results or events, and investors should avoid placing undue
reliance on such statements. Synageva undertakes no obligation to update
any forward-looking statements, whether as a result of new information,
future events or otherwise. Our business is subject to substantial risks
and uncertainties, including those referenced above.
“Dedicated to Rare Diseases®” is a registered trademark of Synageva BioPharma Corp. “Synageva BioPharma™” is a trademark of Synageva BioPharma Corp.
Synageva BioPharma Corp.
Matthew Osborne, 781-357-9947
matthew.osborne@synageva.com
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.